HEPA
Price
$0.47
Change
-$0.01 (-2.08%)
Updated
Apr 3, 04:57 PM (EDT)
Capitalization
516.56K
LSTA
Price
$2.16
Change
+$0.09 (+4.35%)
Updated
Apr 3, 04:08 PM (EDT)
Capitalization
17.84M
34 days until earnings call
Ad is loading...

HEPA vs LSTA

Header iconHEPA vs LSTA Comparison
Open Charts HEPA vs LSTABanner chart's image
Hepion Pharmaceuticals
Price$0.47
Change-$0.01 (-2.08%)
Volume$700
Capitalization516.56K
Lisata Therapeutics
Price$2.16
Change+$0.09 (+4.35%)
Volume$300
Capitalization17.84M
HEPA vs LSTA Comparison Chart
Loading...
HEPA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LSTA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
HEPA vs. LSTA commentary
Apr 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is HEPA is a Hold and LSTA is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 04, 2025
Stock price -- (HEPA: $0.48 vs. LSTA: $2.07)
Brand notoriety: HEPA and LSTA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: HEPA: 513% vs. LSTA: 94%
Market capitalization -- HEPA: $516.56K vs. LSTA: $17.84M
HEPA [@Biotechnology] is valued at $516.56K. LSTA’s [@Biotechnology] market capitalization is $17.84M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.64B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

HEPA’s FA Score shows that 0 FA rating(s) are green whileLSTA’s FA Score has 1 green FA rating(s).

  • HEPA’s FA Score: 0 green, 5 red.
  • LSTA’s FA Score: 1 green, 4 red.
According to our system of comparison, both HEPA and LSTA are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

HEPA’s TA Score shows that 4 TA indicator(s) are bullish while LSTA’s TA Score has 4 bullish TA indicator(s).

  • HEPA’s TA Score: 4 bullish, 2 bearish.
  • LSTA’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, HEPA is a better buy in the short-term than LSTA.

Price Growth

HEPA (@Biotechnology) experienced а -30.22% price change this week, while LSTA (@Biotechnology) price change was -14.81% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -8.57%. For the same industry, the average monthly price growth was -10.69%, and the average quarterly price growth was -14.76%.

Reported Earning Dates

HEPA is expected to report earnings on Aug 30, 2023.

LSTA is expected to report earnings on May 07, 2025.

Industries' Descriptions

@Biotechnology (-8.57% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
LSTA($17.8M) has a higher market cap than HEPA($517K). LSTA YTD gains are higher at: -30.537 vs. HEPA (-97.966). LSTA has higher annual earnings (EBITDA): -22.24M vs. HEPA (-29.39M). LSTA has more cash in the bank: 31.2M vs. HEPA (1.5M). LSTA has less debt than HEPA: LSTA (137K) vs HEPA (2.22M). LSTA has higher revenues than HEPA: LSTA (1M) vs HEPA (0).
HEPALSTAHEPA / LSTA
Capitalization517K17.8M3%
EBITDA-29.39M-22.24M132%
Gain YTD-97.966-30.537321%
P/E RatioN/AN/A-
Revenue01M-
Total Cash1.5M31.2M5%
Total Debt2.22M137K1,623%
FUNDAMENTALS RATINGS
HEPA vs LSTA: Fundamental Ratings
HEPA
LSTA
OUTLOOK RATING
1..100
7177
VALUATION
overvalued / fair valued / undervalued
1..100
36
Fair valued
23
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10097
PRICE GROWTH RATING
1..100
9984
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

LSTA's Valuation (23) in the null industry is in the same range as HEPA (36). This means that LSTA’s stock grew similarly to HEPA’s over the last 12 months.

LSTA's Profit vs Risk Rating (100) in the null industry is in the same range as HEPA (100). This means that LSTA’s stock grew similarly to HEPA’s over the last 12 months.

LSTA's SMR Rating (97) in the null industry is in the same range as HEPA (100). This means that LSTA’s stock grew similarly to HEPA’s over the last 12 months.

LSTA's Price Growth Rating (84) in the null industry is in the same range as HEPA (99). This means that LSTA’s stock grew similarly to HEPA’s over the last 12 months.

LSTA's P/E Growth Rating (100) in the null industry is in the same range as HEPA (100). This means that LSTA’s stock grew similarly to HEPA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
HEPALSTA
RSI
ODDS (%)
Bullish Trend 3 days ago
82%
Bullish Trend 2 days ago
73%
Stochastic
ODDS (%)
N/A
Bullish Trend 2 days ago
84%
Momentum
ODDS (%)
N/A
Bearish Trend 2 days ago
87%
MACD
ODDS (%)
Bullish Trend 2 days ago
75%
Bearish Trend 2 days ago
89%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
88%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
86%
Advances
ODDS (%)
Bullish Trend 15 days ago
77%
Bullish Trend 21 days ago
79%
Declines
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 2 days ago
87%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
86%
Bullish Trend 2 days ago
87%
Aroon
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
79%
View a ticker or compare two or three
Ad is loading...
HEPA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LSTA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TRVG4.600.13
+2.91%
trivago NV
HEPS2.850.02
+0.71%
D-Market Electronic Services & Trading
OGS76.490.28
+0.37%
ONE GAS
WRB69.75-0.50
-0.71%
WR Berkley Corp
MIRA0.95-0.01
-0.73%
MIRA Pharmaceuticals